سعر ستيفارجا 40مجم 3*28 اقراص 2026

Regorafenib 40 mg film-coated tablets, 3 x 28 tablets per pack, by Bayer.

• Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Locally advanced, unresectable or metastatic gastrointestinal stromal tumour previously treated with imatinib and sunitinib.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Hepatocellular carcinoma previously treated with sorafenib.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (20% or more): pain (including gastrointestinal and abdominal pain), hand-foot skin reaction, asthenia/fatigue, diarrhoea, decreased appetite, hypertension, infection, dysphonia, hyperbilirubinaemia, fever, mucositis, weight loss, rash and nausea.International label, same product · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: severe and sometimes fatal hepatotoxicity has occurred; monitor liver function before and during treatment and interrupt, reduce or discontinue based on severity. Fatal hyperammonaemic encephalopathy has been reported post-marketing.International label, same product · DailyMed (U.S. National Library of Medicine)
• Other warnings: infections, haemorrhage, gastrointestinal perforation or fistula, dermatologic toxicity (hand-foot skin reaction), hypertension, cardiac ischaemia and infarction, reversible posterior leukoencephalopathy syndrome, impaired wound healing and embryo-fetal toxicity.International label, same product · DailyMed (U.S. National Library of Medicine)
• Females of reproductive potential, and males with female partners of reproductive potential, should use effective contraception during treatment and for 2 months after the final dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducers (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St John's wort)Decrease regorafenib exposure and may reduce efficacy; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitors (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, voriconazole)Increase regorafenib exposure and may increase toxicity; avoid concomitant use.DailyMed (U.S. National Library of Medicine)

• Based on animal studies and its mechanism of action, regorafenib can cause fetal harm; no human pregnancy data. It was embryolethal and teratogenic in rats and rabbits at exposures below human exposure.International label, same product · DailyMed (U.S. National Library of Medicine)
• No human data; regorafenib and metabolites are excreted in rat milk. Do not breastfeed during treatment and for 2 weeks after the final dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Regorafenib: Small-molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumour angiogenesis, metastasis and tumour immunity (including RET, VEGFR1-3, KIT, PDGFR, FGFR1-2, TIE2, RAF-1 and BRAF) (US label).